Operating

Contingent consideration fair value adjustments

Illumina Contingent consideration fair value adjustments increased by 23.8% to -$16.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 45.5%, from -$11.00M to -$16.00M.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 4, 2026

How to read this metric

Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.

Detailed definition

This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...

Peer comparison

Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.

Metric ID: operating_business_combination_contingent_consideration__7f0be7

Historical Data

15 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q1 '26
Value$0.00-$7.00M$11.00M-$49.00M-$219.00M-$1.00M$29.00M-$110.00M$16.00M-$271.00M-$49.00M-$11.00M-$11.00M-$21.00M-$16.00M
QoQ Change+257.1%-545.5%-346.9%+99.5%>999%-479.3%+114.5%<-999%+81.9%+77.6%+0.0%-90.9%+23.8%
YoY Change<-999%+98.0%+49.8%>999%<-999%+55.5%-168.8%+92.3%-45.5%
Range-$271.00M$29.00M
Avg YoY Growth-253.5%
Median YoY Growth+49.8%

Contingent consideration fair value adjustments at Other Companies

Frequently Asked Questions

What is Illumina's contingent consideration fair value adjustments?
Illumina (ILMN) reported contingent consideration fair value adjustments of -$16.00M in Q1 2026.
How has Illumina's contingent consideration fair value adjustments changed year-over-year?
Illumina's contingent consideration fair value adjustments decreased by 45.5% year-over-year, from -$11.00M to -$16.00M.
What does contingent consideration fair value adjustments mean?
Changes in the estimated cost of future payments owed to sellers of acquired companies based on performance milestones.